Double Bond Pharmaceutical International

Double Bond Pharmaceutical is a Swedish biopharmaceutical company specializing in the development of innovative therapies for orphan diseases, with a core focus on oncology and liver conditions. The company leverages its proprietary BeloGal drug delivery platform to enhance the efficacy and safety of established active pharmaceutical ingredients by targeting them directly to specific organs. Its lead candidate, SI-053, is a local formulation of temozolomide delivered via a hydrogel for the treatment of glioblastoma. Through its subsidiaries, FarmPharma and Drugrecure, the company also explores treatments for viral infections and cardiovascular diseases, maintaining a diverse pipeline of niche therapeutic solutions.